377
Participants
Start Date
August 29, 2019
Primary Completion Date
November 10, 2022
Study Completion Date
November 10, 2022
Botulinum Toxin Type A
Day 1 Administration of bilateral intramuscular injections into the masseter
Placebo
Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
National Taiwan University Hospital /ID# 233133, Taipei City
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 233033, Kaohsiung City
Taipei Medical University Hospital /ID# 233009, Taipei
Tri-Service General Hospital /ID# 233080, Taipei
Peking University First Hospital /ID# 232973, Xicheng District
Peking University Third Hospital /ID# 233148, Beijing
Duplicate_Peking Union Medical College Hospital /ID# 233072, Beijing
Chinese PLA General Hospital /ID# 233158, Beijing
Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine /ID# 232656, Shanghai
Nanjing Drum Tower Hospital /ID# 233016, Nanjing
Zhongda Hospital Southeast University /ID# 232836, Nanjing
Tianjin Medical University General Hospital /ID# 232961, Tianjin
Xiangya Hospital Central South University /ID# 233027, Changsha
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 233008, Wuhan
West China Hospital, Sichuan University /ID# 233107, Chengdu
Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 233087, Xi’an
Duplicate_Beacon Dermatology Inc /ID# 233018, Calgary
Duplicate_Humphrey Cosmetic Dermatology /ID# 232764, Vancouver
Project Skin MD LTD /ID# 232763, Vancouver
Pacific Derm /ID# 233156, Vancouver
The Center For Dermatology /ID# 233001, Richmond Hill
Lead Sponsor
AbbVie
INDUSTRY